Wednesday, July 8, 2026

Patent intelligence · US

US 12053477

Methods for treating pulmonary fibrosis

granted A61KA61K31/538A61K9/0053A61P
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 28
Patent details — US 12053477
Jurisdiction
US
Status
granted
Grant date
Aug 6, 2024
Expiration
Aug 1, 2044
Claims
9
CPC classes
A61K, A61K31/538, A61K9/0053, A61P
View on Google Patents ↗

Quick answer

US 12053477 (Methods for treating pulmonary fibrosis) is held by REVIVA PHARMACEUTICALS, INC.. Status: granted. Granted Aug 6, 2024. Expires Aug 1, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
9
CPC classes
A61K, A61K31/538, A61K9/0053, A61P, A61P11/00

More from REVIVA PHARMACEUTICALS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 10441590

    Methods for treating pulmonary hypertension

    REVIVA PHARMACEUTICALS, INC. · Expires Oct 10, 2039

    granted
  2. US 10035761

    Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

    REVIVA PHARMACEUTICALS, INC. · Expires Jul 26, 2038

    granted
  3. US 9975862

    Arylpiperazine derivatives and methods of utilizing same

    REVIVA PHARMACEUTICALS, INC. · Expires May 17, 2038

    granted
  4. US 9907803

    Methods for treating attention deficit hyperactivity disorder

    REVIVA PHARMACEUTICALS, INC. · Expires Mar 1, 2038

    granted
  5. US 9695116

    Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

    REVIVA PHARMACEUTICALS, INC. · Expires Jun 29, 2037

    granted
  6. US 9604944

    Arylpiperazine derivatives and methods of utilizing same

    REVIVA PHARMACEUTICALS, INC. · Expires Mar 23, 2037

    granted
  7. US 9302981

    Synthesis, methods of using, and compositions of cycloalkylmethylamines

    REVIVA PHARMACEUTICALS, INC. · Expires Mar 31, 2036

    granted

Frequently asked questions

What is US patent 12053477?

US 12053477 (Methods for treating pulmonary fibrosis) is held by REVIVA PHARMACEUTICALS, INC.. Status: granted. Granted Aug 6, 2024. Expires Aug 1, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12053477?

REVIVA PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 28 pharmaceutical patents for this assignee.

When does US 12053477 expire?

Our index shows an expiration date of Aug 1, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.